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Background: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that is secreted from bone and serum
level increases as renal function declines. Higher levels of FGF23 are associated with increased mortality in
hemodialysis-patients and in patients with chronic kidney disease (CKD) stage 2-4. The use of active vitamin D and
phosphate binders as recommended in international guidelines, may affect the level of FGF23 and thereby clinical
outcome. We investigated the effects of a phosphate binder and active vitamin D on the serum levels of intact
FGF23 (iFGF23) and intact parathyroid hormone (iPTH) in patients with CKD stage 3b (glomerular filtration rate
(GFR) 30–44 ml/min/1.73 m2).
Methods: Seven women and 14 men were included, mean age 65.6 ± 12.2 years. They were randomized in a 1:1
ratio to receive one of two treatment sequences. Group-1 (the alphacalcidol-sevelamer carbonate group):
alphacalcidol 0.25 μg once daily for two weeks followed by sevelamer carbonate 800 mg TID with meals for two
weeks after a two-week washout period. Group-2 (the sevelamer carbonate-alphacalcidol group): vice versa.
Nineteen patients completed the study. The 25-hydroxyvitamin D level at baseline was 97.6 ± 25.0 nmol/l.
Results: There were no treatment effects on the iFGF23 and iPTH levels overall. In group-1 the iFGF23 level was
higher after treatment with alphacalcidol compared with sevelamer carbonate (mean 105.8 ± 41.6 vs. 79.1 ± 36.5
pg/ml, p = 0.047 (CI: 0.4-52.9), and the iPTH level was lower (median: 26.5, range: 14.6-55.2 vs. median 36.1, range
13.4-106.9 pg/ml, p = 0.011). In group-2 the iFGF23 level increased non-significantly after treatment with sevelamer
carbonate and throughout the washout period.
Conclusions: In this crossover trial with alphacalcidol and sevelamer carbonate in patients with CKD stage 3b, the
levels of iFGF23 were not significantly different after the two treatments. However, in the group of patients
initiating therapy with sevelamer carbonate the iFGF23 levels seemed to increase while this response was mitigated
in the group of patients given alphacalcidol followed by sevelamer carbonate. This may have therapeutic
implications on choice of first line therapy. The number of patients is small and this conclusion is in part based on
subgroup analysis. It is therefore important that these results are confirmed in larger studies.
Trial registration: Trial Registration Number: European Clinical Trial Database (EudraCT) 2010-020415-36 and
Clinical Trials.gov NCT01231438
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Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease (CKD) and is
characterized by abnormalities in serum calcium, serum
phosphate, parathyroid hormone (PTH) concentrations,
vitamin D metabolism, and bone turnover. SHPT is
associated with increased cardiovascular disease, total
mortality, and vascular calcifications [1]. Treatment
guidelines for the evaluation and management of
patients with chronic kidney disease-mineral and bone
disorder (CKD-MBD) were published in 2009 [2] but
there are to date no prospective trials documenting a
survival advantage for any of the therapeutic treatment
options available [3].
Phosphate retention occurs early in the course of renal
failure and there are data in favor of the hypothesis that
this is the principal abnormality of SHPT [4]. Fibroblast
growth factor 23 (FGF23), a phosphaturic hormone,
plays an important role in phosphate homeostasis.
FGF23 secretion from bone increases as renal function
declines [5]. FGF23 increases urinary phosphate excre-
tion and can be viewed as an adaptive response to phos-
phate load. Klotho, a transmembrane protein, is mainly
expressed in renal tubular cells, the parathyroid gland,
and the choroid plexus and is an obligate co-receptor
for FGF23 [6]. FGF23 inhibits 1,25-dihydroxyvitamin D
(1,25 (OH)2D) production by inhibiting 1-α hydroxylase
and stimulating 24-α hydroxylase thus acting as an anti-
vitamin D agent. In CKD the expression of Klotho is
reduced in the kidneys and also in the parathyroid
glands [7]. This may explain the FGF23 resistance in
parathyroid glands resulting in increased levels of both
FGF23 and PTH in patients with renal failure [6].
Higher levels of FGF23 are associated with increased
mortality in hemodialysis-patients even after correcting
for phosphate levels and in patients with CKD stage 2–4
[8,9]. The use of active vitamin D and phosphate bindersTable 1 Patient characteristics at inclusion
Total N= 21 Group - 1
first N= 1
Age (years) 65.6 ± 12.2 65.7 ± 9.6
Sex (males, females) 14 - 7 7 - 4
Body mass index (kg/m2) 26.4 ± 3.4 25.8 ± 4.0
SBP (mmHg) 132 (115–194) 132 (115–
DBP (mmHg) 84 (76–114) 85 (78–11
Creatinine (μmol/l) 154.4 ± 25.5 149.9 ± 27
eGFR (ml/min/1.73 m2) 36.6 ± 5.6 37.6 ± 6.5
Albumin/creatinin ratio (mg/mmol)d 1.4 (0.2-95.0) 1.7 (0.2-95
Mean± SD for normally distributed data, otherwise median and range.
at-test for normally distributed variables.
bchi-squared test for categorical variables.
cMann-Whitney U-testing of non-parametric continuous variables.
dmeasured at study end.as recommended in international guidelines may affect
the levels of FGF23 and thereby clinical outcome. We
investigated the effects of a calcium-free phosphate
binder and active vitamin D on the serum levels of intact
FGF23 (iFGF23) and intact PTH (iPTH) in patients with
CKD stage 3b.
Methods
The study was designed as a single-center, randomized,
open-label crossover study. Patients aged ≥ 18 years with
CKD stage 3b (glomerular filtration rate (GFR) 30–
44 ml/min/1.73 m2) were recruited from the nephrology
outpatient clinic at Stavanger University Hospital. The
study adhered to the Declaration of Helsinki and was
approved by the Regional Medical and Health Research
Ethics Committees (REC) Western Norway. The study
was registered in the European Clinical Trial Database
(EudraCT 2010-020415-36) and at Clinical Trials.gov
NCT01231438. Written informed consent was obtained
from all patients prior to inclusion.
Patients were excluded if they had had major surgery
or a myocardial infarction within the last six months,
were under active treatment for malignant disease, or
any other clinically significant unstable medical condi-
tion. Patients who were on medical treatment with lith-
ium, corticosteroids and/or bisphosphonates potentially
influencing mineral metabolism were also excluded.
None of the patients received treatment with any form
of active vitamin D medication or phosphate binders
prior to study start.
Twenty-one patients were included, seven women and
14 men, mean age 65.6 ± 12.2 years. They were randomized
in a 1:1 ratio to two treatment groups, Table 1. Group-1
received alphacalcidol (EtalphaW) 0.25 μg once daily for
two weeks followed by two weeks washout and then seve-
lamer carbonate (RenvelaW) 800 mg TID with meals (the
alphacalcidol – sevelamer carbonate group). Group-2: alphacalcidol
1
Group - 2: sevelamer carbonate
first N= 10
p-value
65.5 ± 15.1 0.98a
7 - 3 0.76b
27.1 ± 2.7 0.40a
194) 133 (123–167) 0.89c
4) 84 (76–99) 0.57c
.7 159.4 ± 23.3 0.41a
35.6 ± 4.6 0.44a
.0) 1.1 (0.3-32.0) 0.83c
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meals followed by two weeks washout and then alphacalci-
dol (EtalphaW) 0.25 μg once daily for two weeks (the seve-
lamer carbonate – alphacalcidol group). Doses were not
adjusted during the treatment periods. The levels of 25-
hydroxyvitamin D (25(OH)D) were analyzed before inclu-
sion, and if 25(OH)D levels were < 40 nmol/l, they were
given ergocalciferol (vitamin D2) 1.5 mg (two tablets of
AFI-D2 forte
W á 0.75 mg equivalent of 60 000 IU vitamin
D2) every week for four weeks (a total of 8 tablets) and
their 25(OH)D levels were then re-analyzed. If 25(OH)D
levels were < 50 nmol/l but > 40 nmol/l they were given a
total of 6 tablets of AFI-D2 forte
W over three weeks. They
were included when the 25(OH)D levels were> 50 nmol/l.
In Norway, the patients with CKD stage 3b are not
given specific dietary advice. The phosphate content of
beverages and phosphate additives in addition to the pro-
tein content of the diet is of utmost importance for the
renal patients at risk of hyperphosphatemia [10]. Restric-
tions in intake are not advocated at this level of renal
function, and since the study was carried out in a way to
mimic standard clinical care, no advice was given other
than asking the patients to continue with their usual diet
and keep it stable during the study period. Blood samples
were drawn in the morning after breakfast. A fasting
morning urine specimen was delivered at every visit.
Compliance was monitored by pill counts. Two patients
stopped taking sevelamer carbonate due to gastrointestinal
side effects, one due to reflux symptoms, one due to con-
stipation. These two patients were excluded from the ana-
lysis of the crossover study as a whole. Groups were
otherwise unchanged as the randomization was not strati-
fied and there was no reason to believe that the effect of
the medication and the type of side effects were coupled in
any way. The remainder of the patients took 93% of the
prescribed doses of sevelamer carbonate. None of the
patients experienced side effects of alphacalcidol and they
took 99% of the prescribed doses. Two patients (one in
each treatment group) had a washout period of four weeks
due to winter holidays.
Patient characteristics: The underlying causes of CKD
were hypertension (n= 6), adult polycystic kidney disease
(n=6), glomerulonephritis (n =4) and unknown (n=5). All
but four patients were on antihypertensives: five patients
on β-blockers, three on combined α- and β blockers, six
on angiotensin-converting enzyme (ACE) inhibitors, 11 on
angiotensin II (ARB) receptor blockers, six on calcium
channel blockers, four on loop-diuretics, six on thiazid-
diuretics, and two patients on spironolactone. Nine
patients were on platelet inhibitors, 13 patients on
cholesterol- lowering therapy (statins 12 patients, ezeti-
mibe one patient), and six patients were on prophylactic
anti-gout medication (xanthine oxidase inhibitors 5
patients, febuxostat one patient).CKD stage 3b was defined as estimated GFR (eGFR)
30–44 ml/min/1.73 m2 estimated by means of the modifi-
cation of diet in renal disease (MDRD) method [11].
White blood cell count and concentrations of hemoglobin,
creatinine, total serum calcium, phosphorus, total alkaline
phosphatase and albumin were determined at every visit
using a computerized auto-analyzer. Serum and EDTA-
plasma were then stored at −72°C for later measurements
of iFGF23, iPTH, 25(OH)D and 1,25(OH)2D. Samples for
markers of bone turnover: cross-linked N-telopeptides of
bone type I collagen (NTx) as a bone-resorption marker
and osteocalcin, bone-specific alkaline phosphatase
(BALP) and intact N-terminal propeptide of type I procol-
lagen (PINP) as bone-formation markers were stored in
the same manner. These samples were then analyzed in
one run in order to minimize analytical variability. All
samples were measured in duplicate, with serial samples
from a given individual run at the same time. Intra- and
inter-assay coefficient of variation were <10% for all
assays. Serum iFGF23 was measured by sandwich ELISA
(Kainos Laboratories Inc., Tokyo, Japan), plasma iPTH by
a radioimmunoassay (Scantibodies Laboratory, Inc., CA,
U.S.A.) and serum 25(OH)D (DiaSorin, Minnesota, U.S.
A.) and plasma 1,25(OH)2D (Immunodiagnostic Systems
Nordic, Denmark) were quantified by radioimmunoassay
(RIA). NTx in serum was determined by an enzyme-
linked immuno-sorbent essay (ELISA/EIA, Wampole
Laboratories Inc. Princeton, USA), as were serum
osteocalcin and BALP (EIA, Quidel Corp. San Diego,
USA). PINP was determined by RIA from Orion
Diagnostica, Finland.
Urine samples were analyzed for concentrations of phos-
phate and creatinine at every visit and albumin at the last
visit. The fractional excretion of phosphate (FePO4) was
calculated as follows: (urine phosphate*serum creatinine)
*100/(serum phosphate*urine creatinine).
Statistical analysis
The primary end-points of the study were the differ-
ences in the levels of iFGF23 and iPTH after each treat-
ment period. The secondary end-points were the
differences in the levels of FePO4, calcium, phosphate,
vitamin D metabolites and markers of bone turnover
after each treatment period. The tests for period effects
and carry-over effects were performed before the treat-
ment effects were examined for the crossover study as a
whole [12]. The two-sample t approach was then used to
analyze treatment effects by comparing the period-
differences (level after period 1 minus level after period
2) of the different end-points for normally distributed
data otherwise the Mann–Whitney U test for independ-
ent samples was used [13]. The repeated measurement
analysis of variance (ANOVA) was used to investigate
changes over time for normally distributed data. When
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were performed to obtain difference estimates and confi-
dence intervals. When analyzing the differences over
each period for the two groups separately, the paired
samples t-test was used for normally distributed data,
otherwise the Wilcoxon signed rank test for related sam-
ples was used. Differences were considered statistically
significant at a p level of ≤ 0.05. All analyses were per-
formed using the PASW Statistics version 18.0 (SPSS
Inc, Chicago, IL).
Power analysis
The primary end point, the difference in FGF23 levels
between the two treatment periods in the two groups,
would be analyzed with an independent two-sample t
test. We found it reasonable to hypothesize that sevela-
mer carbonate therapy could bring the FGF23 levels in
early CKD back to the range seen in healthy individuals.
In dialysis patients, intravenous calcitriol therapy
increased FGF23 levels and the increase was dose-
dependent [14]. A conservative estimate of the alphacal-
cidol effect on FGF23 levels would thus be zero. The
treatment period difference was then estimated to be
32 ng/ml [15]. We did not have any estimate of the
standard deviation (SD) of the difference, but this is
often lower than the SD of the measurements. We there-
fore chose to use the SD of the measurements as a con-
servative estimate of the SD of the difference [16]. With
Δ 32, SD 24 and α 0.05 the power was 80% with 10
patients in each group.
Results
The iFGF23 levels at baseline were > 50 pg/ml for all but
one patient, Table 2 (range in healthy adults 8.2 –
54.3 pg/ml [17]).
There was no significant period or carry-over effect on
the iFGF23 (p = 0.056 and p = 0.234) or iPTH levels
(p = 0.315 and p = 0.315). There was no significant treat-
ment effect on iFGF23 (Figure 1) or iPTH levels
(p = 0.667 and p = 0.243 respectively).
There was no significant period effect (p = 0.908) or
carry-over effect (p = 0.109) on FePO4. There was a sig-
nificant treatment effect with a higher urinary excretion
of phosphate after two weeks of treatment with alphacal-
cidol compared with sevelamer carbonate (mean differ-
ence 4.4%, p = 0.028, CI: 0.6-8.3).
There was no treatment effect on the bone-resorption
marker NTx, the bone-formation markers BALP, osteo-
calcin and PINP. Despite treatment with alphacalcidol,
the 1,25(OH)2D levels were unchanged. There were no
treatment effects on serum calcium and phosphate
levels, Table 2.
There was no difference in creatinine levels and eGFR
measurements between the two groups at baseline orduring the study. For the two groups combined the cre-
atinine levels were significantly higher (mean difference
9.2 μmol/l, CI: 2.9-15.5, p = 0.007) and the eGFR levels
were significantly lower (mean difference 2.1 ml/min/
1.73 m2, CI: 0.5-3.7, p = 0.011) at the end of the study
compared with the start of the study. The magnitude of
the reduction in eGFR during the study although statis-
tical significant, is unlikely to have had any effect on the
result of the study. There was no difference in 25(OH)D
levels between the two groups during the study. There
was a trend toward lower levels at the end of the study
compared with the earlier visits, but the trend was not
statistically significant (p = 0.075).
Within-groups comparisons
Group-1, the alphacalcidol – sevelamer carbonate group
The iFGF23 level was higher after treatment with alpha-
calcidol compared to sevelamer carbonate, (mean
105.8 ± 41.6 vs. 79.1 ± 36.5 pg/ml, p = 0.047 (CI: 0.4-52.9),
for iPTH lower (median: 26.5, range: 14.6-55.2 vs. me-
dian 36.1, range 13.4-106.9 pg/ml, p = 0.011).
iFGF23 tended to be higher after treatment with
alphacalcidol compared to baseline, but it did not reach
clinical significance (p = 0.070), Figure 2. FePO4 was sig-
nificantly higher after treatment with alphacalcidol
(mean difference 6.7%, CI: 2.3-11.1, p = 0.007). There
was no effect of alphacalcidol on the iPTH levels
(p = 0.083).
iFGF23 was significantly lower after treatment with
sevelamer carbonate compared to the level before initi-
ation of treatment (mean difference 23.4 pg/ml, CI:
1.4-45.5, p = 0.040). There was no effect of sevelamer
carbonate treatment on FePO4 (p = 0.366) or the iPTH
levels (p = 0.678), Figure 1.
Group-2 the sevelamer carbonate – alphacalcidol group
The iFGF23 levels increased non-significantly after treat-
ment with sevelamer carbonate (p = 0.169) and through-
out the washout period (p = 0.074), Figure 2. There was
no effect of sevelamer carbonate on FePO4 (p = 0.597)
or on the iPTH levels (p = 0.878).
There were no effects of alphacalcidol on the iFGF23
levels (p = 0.168), FePO4 (p = 0.482), or the iPTH levels
(p = 0.284) when alphacalcidol followed sevelamer car-
bonate therapy.
The two patients with a washout period of four weeks
responded to the two treatments in accordance with the
rest of the patients in their group.
Discussion
In this six-week crossover study in CKD patients stage
3b there were no treatment effects on the iFGF23 (Fig-
ure 1) or iPTH levels.
Table 2 Biochemical parameters for all patients at baseline (week 0), after the first treatment period (week 2), after
washout (week 4) and after the second treatment period (week 6)
Groupa Baseline After the first
treatment period
After washout After the second
treatment period
calcium (mmol/l) mean± SD 1 2.33 ± 0.10 2.34 ± 0.11 2.35 ± 0.08 2.33 ± 0.07
2 2.28 ± 0.07 2.30 ± 0.12 2.31 ± 0.11 2.34 ± 0.11
phosphate (mmol/l) mean± SD 1 1.08 ± 0.24 1.11 ± 0.24 1.16 ± 0.20 1.11 ± 0.19
2 1.03 ± 0.21 1.01 ± 0.18 1.04 ± 0.17 1.05 ± 0.19
creatinine (μmol/l) mean± SD 1 141.1 ± 29.7 143.4 ± 27.1 138.9 ± 29.1 146.6 ± 35.1
2 156.9 ± 26.8 166.2 ± 24.7 158.3 ± 21.6 169.5 ± 29.6
eGFR (ml/min/1,73 m2) mean± SD 1 40.1 ± 7.0 38.9 ± 6.0 40.8 ± 7.7 38.9 ± 7.7
2 36.4 ± 5.0 33.8 ± 2.7 35.6 ± 3.3 33.5 ± 6.3
25(OH) vitD (nmol/l) mean± SD 1 99.4 ± 23.7 94.9 ± 22.3 93.8 ± 26.1 86.1 ± 18.0
2 88.0 ± 22.0 86.6 ± 25.6 84.4 ± 31.0 85.6 ± 30.6
FePO4 (%)
b mean± SD 1 26.8 ± 6.7 33.5 ± 9.1 31.7 ± 11.6 29.3 ± 8.6
2 34.5 ± 9.5 36.3 ± 10.5 38.1 ± 12.2 41.0 ± 11.7
1.25(OH)2 vitD (pmol/l) median, range 1 72.0 (23.0-112.0) 70.0 (29.0-130.0) 64.0 (32.0-94.0) 61.0 (32.0-108.0)
2 65.5 (46.0-175.0) 56.6 (37.0-125.0) 70.0 (27.0-89.0) 60.5 (37.0-99.0)
FGF23 (pg/ml) mean± SD 1 90.7 ± 28.4 105.8 ± 41.6 102.6 ± 33.1 79.1 ± 36.5
2 110.2 ± 73.7 127.6 ± 76.6 142.3 ± 52.2 110.4 ± 41.7
PTH (pg/ml) median, range 1 35.9 (16.3-147.4) 26.5 (14.6-55.2) 35.0 (14.3-72.5) 36.1 (13.4-106.9)
2 35.3 (22.6-73.9) 38.7 (21.2-61.0) 33.7 (23.6-63.1) 37.7 (19.7-71.3)
PINP (μg/l) median, range 1 56.5 (23.2-115.6) 53.0 (24.5-133.8) 52.8 (30.0-89.7) 60.8 (28.3-82.2)
2 36.9 (17.1-55.6) 40.5 (20.3-61.4) 37.9 (17.5-55.4) 38.4 (16.8-49.2)
Osteocalcin (ng/ml) median, range 1 17.3 (7.6-37.7) 18.1 (8.9-38.7) 16.5 (9.4-35.6) 18.1 (9.6-34.9)
2 12.8 (7.4-25.2) 13.5 (7.7-28.0) 13.6 (9.7-24.5) 13.4 (10.5-26.4)
BALP (U/L) median, range 1 24.3 (14.7-43.4) 22.8 (13.0-37.8) 25.1 (13.0-39.3) 27.1 (13.7-41.2)
2 17.9 (12.7-32.0) 19.7 (10.8-33.0) 19.2 (9.4-35.1) 21.3 (11.6-36.6)
NTx (nM BCE)c median, range 1 16.8 (10.3-77.0) 14.4 (10.4-54.8) 13.6 (10.2-25.6) 13.9 (11.1-42.2)
2 13.2 (5.9-34.3) 11.9 (7.3-18.3) 11.8 (6.9-21.4) 14.1 (8.0-22.1)
aGroup-1: The alphacalcidol-sevelamer group: alphacalcidol for two weeks (first treatment period) followed by sevelamer carbonate (second treatment period)
after two weeks washout (data shown for the nine patients that completed the crossover study).
Group-2: The sevelamer-alphacalcidol group: sevelamer carbonate for two weeks (first treatment period) followed by alphacalcidol (second treatment period) for
two weeks after two weeks washout.
bThe treatment difference was statistically significant (p = 0.028).
cnM BCE = nmol Bone Collagen Equivalents.
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phate in the alimentary tract and thereby decrease phos-
phate absorption. Reduced phosphate absorption over
five to nine days reduces the levels of FGF23 in healthy
humans [18-21]. We therefore expected a reduction in
iFGF23 levels after the intervention period with a phos-
phate binder. The baseline levels of serum phosphate and
iPTH were however low in our cohort of patients indicat-
ing a low dietary intake of phosphate. The potential effect
of a phosphate binder may therefore be reduced.
Our results are in accordance with a study of dietary
phosphate restriction and therapy with lanthanum carbon-
ate of two weeks’ duration in which the levels of FGF23
were not reduced [22]. However, this is in contrast to a
four-week study with lanthanum carbonate and a six-week
study of sevelamer hydrochloride where the levels ofFGF23 were reduced [23,24]. The authors of the two-week
study hypothesized that an intervention period of two
weeks was too short to reduce the FGF23 levels. In the
group of patients that received alphacalcidol as the first
line of therapy in our study, the iFGF23 level was however
significantly lower (p=0.040) after two weeks of sevelamer
carbonate treatment compared with the level before initiat-
ing therapy. This suggests that an intervention period of
two weeks in itself is not too short to induce a reduction in
iFGF23 levels even in CKD patients.
One of the strengths of this study is that it includes an
active form of vitamin D in the treatment regiment and
that the 25(OH) vitamin D levels at inclusion and during
the study were sufficient. Active vitamin D enhances phos-
phate absorption from the alimentary tract through the







Figure 1 Delta iFGF23 levels. Box plot of Δ intact fibroblast growth factor 23 (iFGF23): mean iFGF23 level after the first treatment period minus
mean iFGF23 level after the second treatment period. Group-1: the alphacalcidol – sevelamer carbonate group: alphacalcidol for two weeks (first
treatment period) followed by sevelamer carbonate for two weeks (second treatment period) after two weeks washout. Group-2: the sevelamer
carbonate – alphacalcidol group: sevelamer carbonate for two weeks (first treatment period) followed by alphacalcidol for two weeks (second
treatment period) after two weeks washout.
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phate reabsorption by inducing the renal sodium-
phosphate co-transporter NaPi-IIc [25]. Infusion of 1,25




























Figure 2 Mean iFGF23 levels and study design. The mean level
of intact fibroblast growth factor 23 (FGF23) for each group at
baseline (week 0), after the first treatment period (week 2), after
washout (week 4) and after the second treatment period (week 6).
Bars indicate SEM. Group-1: the alphacalcidol – sevelamer carbonate
group: alphacalcidol for two weeks (first treatment period) followed
by sevelamer carbonate for two weeks (second treatment
period) after two weeks washout. Group-2: the sevelamer
carbonate – alphacalcidol group: sevelamer carbonate for two
weeks (first treatment period) followed by alphacalcidol for two
weeks (second treatment period) after two weeks washout.dialysis patients [14]. Active vitamin D exerts a direct effect
on the parathyroid gland which leads to reduced excretion
of PTH [6]. The net effect of vitamin D treatment is thus
difficult to predict, and it is important to include this treat-
ment regimen in clinical studies. The levels of calcium,
iPTH and 1.25(OH)2D did not change during the study.
This may be due to the relatively low dose of alphacalcidol
given (0.25 μg once daily).
Although we did not perform bone-biopsies, which are
the gold standard in assessing bone turnover, one of the
strengths of the study is the characterization of markers of
bone turnover. Either the bone-resorption marker or the
bone-formation markers’ changed during the study indicat-
ing a steady state of bone turnover. Urinary phosphate ex-
cretion during a steady state of bone turnover is mainly
determined by phosphate absorption from the alimentary
tract [27]. The changes in urinary phosphate excretion dur-
ing the study can thus be attributed to changes in phos-
phate absorption. The FePO4 was higher after treatment
with alphacalcidol compared with sevelamer carbonate
overall (mean difference 4.4%, p=0.028, CI: 0.6-8.3) con-
sistent with increased phosphate absorption.
Our study is a crossover study, and this design has its
limitations. The validity of the results of a crossover trial
depends on the study results only being affected either
by treatment effects or chance. If there are interactions
between period and treatment, the crossover study as a
whole can no longer be analyzed in an ordinary way and
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treatment period for both groups.
The statistical testing for a period effect was negative for
all the samples analyzed. The results for iFGF23 were on
the other hand unexpectedly lower in the second period
than in the first period in both groups (Figure 2). But if a
period effect was present, for example by increased dietary
phosphate intake at Christmas-time, we would expect the
levels of iFGF23 to increase in the second treatment
period, not decrease.
The statistical testing for a carry-over effect was also
negative for all the samples analyzed. When examining
the results for each group separately (Figure 2), one can
see that the iFGF23 levels have not returned to their
pre-treatment levels after the washout period. A carry-
over effect could explain this finding thus indicating that
the statistical test simply was underpowered due to small
sample size. In a study with sevelamer hydrochloride,
Oliveira et al showed that the iFGF23 levels did return
to pre-treatment levels two weeks after study end [24].
In group-1, the iFGF23 levels tended to decrease during
the washout period although they did not return to pre-
treatment levels. This is in contrast to the iFGF23 levels
in group-2 that continued to rise during the washout
period. The patients were asked to continue with their
diet unchanged and the dietary advice was the same for
the two groups. It is thus unlikely that the rise in iFGF23
levels after sevelamer carbonate therapy in group-2 was
a result of phosphate loading. There was also no signifi-
cant change in FePO4 in these patients indicating a
stable phosphate intake.
The difference between the two groups is striking. We
suggest that the reason is an order effect that is clinically
interesting and not a result of dietary changes or a treat-
ment by period interaction (carry-over effect). The
patients who received alphacalcidol first responded to
sevelamer carbonate treatment with a reduction in
iFGF23 levels as expected in contrast to patients receiv-
ing sevelamer carbonate first. This could be due to an
unknown effect of active vitamin D mediated by the
gastrointestinal tract. Data in favor of an “intestinal fac-
tor” involved in phosphate homeostasis is emerging [28].
It has been demonstrated that installation of phosphate
in the duodenum of normal rats rapidly increased renal
excretion of phosphate without accompanying FGF23
elevations [29]. In humans, intravenous infusion of phos-
phate increased serum phosphate levels but FGF23 levels
did not change for up to six hours [30]. Meals contain-
ing 1200 mg inorganic phosphate increased FGF23 levels
but not until after 8 hours [31]. The route of administra-
tion and the duration of the phosphate load appear to be
of importance.
Despite small sample size and the limitations of the
study due to the crossover design, the results of ourstudy should be interesting for clinicians planning future
studies. The questions raised also emphasize the need to
include active vitamin D in studies evaluating treatment
effects on iFGF23 levels.
Conclusions
Our findings are challenging and suggest that treatment
with sevelamer carbonate may have to be preceded by
alphacalcidol in order to reduce iFGF23 levels during the
initial phase of treatment. Alphacalcidol given alone may
on the other hand increase iFGF23 levels. This may have
therapeutic implications and needs confirmation in larger
studies.
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